Nuclear Galectin-1 promotes KRAS -dependent activation of pancreatic cancer stellate cells
Proceedings of the National Academy of Sciences · 2025
DOI: 10.1073/pnas.2424051122 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2025. Verfasst von Judith Vinaixa und 17 weiteren Autor:innen. Beteiligte Einrichtung: Cancer Research Program, Hospital del Mar Research Institute, Barcelona 08003, Spain. Hauptthemen laut MEDLINE: Galectin 1, Pancreatic Stellate Cells, Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras). Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Institutes of Health (NIH), Spanish Ministry of Science and Innovation (MICINN)/ Instituto de Salud Carlos III, Agencia Argentina de Investigacion, Desarrollo e Innovación.
Abstract (Originalsprache)
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive cancers, primarily due to its complex tumor microenvironment (TME), which drives both disease progression and therapy resistance. Understanding the molecular mechanisms governing TME dynamics is essential for developing new treatment strategies for this devastating disease. In this study, we uncover an oncogenic role for Galectin-1 (Gal1), a glycan-binding protein abundantly expressed by activated pancreatic stellate cells (PSCs), a key component of the PDAC TME that orchestrates tumor progression. Our findings reveal that Gal1 expression is elevated in the nucleus of human PSCs in both tissue samples and cultured cell lines. Using chromatin immunoprecipitation followed by sequencing analysis (ChIP-seq), we identify Gal1 occupancy at the promoters of several cancer-associated genes, including KRAS , a pivotal oncogene involved in PDAC pathogenesis. We demonstrate that Gal1 binds to the KRAS promoter, sustaining KRAS expression in PSCs, which, in turn, maintains PSC activation and promotes the secretion of protumorigenic cytokines. Mechanistically, Gal1 is required to preserve histone H3 lysine 4 monomethylation levels and to recruit the histone methyltransferase MLL1 to target promoters. Collectively, our findings define a nuclear function of Gal1 in modulating the transcriptional landscape of cancer-associated genes in PSCs within the PDAC TME, mediated through an epigenetic mechanism. These insights enhance our understanding of PDAC pathology and open potential avenues for therapeutic interventions targeting intracellular Gal1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Cancer Research Program, Hospital del Mar Research Institute, Barcelona 08003, Spain.
- Cancer Research Program, Hospital del Mar Research Institute, Associated Unit Hospital del Mar Research Institute/Institute of Biomedical Research of Barcelona-Spanish National Research Council (IIBB-CSIC), Barcelona 08…
- Translational Research and Innovative Therapies Department, Cancer Research Center of Marseille, INSERM U1068, Institut Paoli-Calmettes, Aix-Marseille University, CNRS, UMR 7258, Marseille 13273, France.
- Laboratorio de Glicomedicina, Instituto de Biología y Medicina Experimental, Consejo Nacional de Investigaciones Científicas y Técnicas, Ciudad de Buenos Aires 1428, Argentina.
- Departamento de Ciencias Básicas, Universidad Nacional de Luján, Luján 6700, Provincia de Buenos Aires, Argentina.
- Schulze Center for Novel Therapeutics, Division of Oncology Research, Department of Oncology, Mayo Clinic, Rochester, MN 55905.
ORCID-Profile: Patricia Santofimia-Castaño, Juan L Iovanna, Gabriel A Rabinovich
Förderung
- National Institutes of Health (NIH)
- Spanish Ministry of Science and Innovation (MICINN)/ Instituto de Salud Carlos III
- Agencia Argentina de Investigacion, Desarrollo e Innovación
- Fundación René Barón (Fundacion Rene Baron)
- NCI NIH HHS
- Ministro de Ciencia, Tecnologia e Innovacion de Argentina
- Asociacion Cancer Pancreas/Asociacon Espanola Pancreatologiaa
- Fundación Sales (Sales Foundation)
Zitieren
APA
Vinaixa, J., Martínez-Bosch, N., Gibert, J., Manero-Rupérez, N., Santofimia-Castaño, P., Baudou, F. G., Vera, R. E., Pease, D. R., Iglesias, M., Sen, S., Wang, X., Almada, L. L., Marks, D. L., Moreno, M., Iovanna, J. L., Rabinovich, G. A., Fernandez-Zapico, M. E., & Navarro, P. (2025). Nuclear Galectin-1 promotes KRAS -dependent activation of pancreatic cancer stellate cells. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2424051122
Vancouver
Vinaixa J, Martínez-Bosch N, Gibert J, Manero-Rupérez N, Santofimia-Castaño P, Baudou FG, et al. Nuclear Galectin-1 promotes KRAS -dependent activation of pancreatic cancer stellate cells. Proceedings of the National Academy of Sciences. 2025. doi:10.1073/pnas.2424051122
BibTeX
@article{Vinaixa2025,
author = {Vinaixa, Judith and Martínez-Bosch, Neus and Gibert, Joan and Manero-Rupérez, Noemí and Santofimia-Castaño, Patricia and Baudou, Federico G and Vera, Renzo E and Pease, David R and Iglesias, Mar and Sen, Sandhya and Wang, Xiyin and Almada, Luciana L and Marks, David L and Moreno, Mireia and Iovanna, Juan L and Rabinovich, Gabriel A and Fernandez-Zapico, Martin E and Navarro, Pilar},
title = {Nuclear Galectin-1 promotes KRAS -dependent activation of pancreatic cancer stellate cells},
journal = {Proceedings of the National Academy of Sciences},
year = {2025},
doi = {10.1073/pnas.2424051122}
}
EUVIMED